Management of CMV retinitis in HIV infected patients.
作者信息
Katlama C
机构信息
Department of Infectious and Tropical Diseases, Hôpital Pitlé-Salpêtrière, Paris, France.
出版信息
Genitourin Med. 1997 Jun;73(3):169-73. doi: 10.1136/sti.73.3.169.
Abstract
摘要
相似文献
1
Management of CMV retinitis in HIV infected patients.
Genitourin Med. 1997 Jun;73(3):169-73. doi: 10.1136/sti.73.3.169.
2
Management of CMV infections in HIV-infected patients.
Adv Exp Med Biol. 1999;458:77-87. doi: 10.1007/978-1-4615-4743-3_8.
3
New developments in the treatment of CMV retinitis.
Ophthalmology. 1996 Jul;103(7):999-1000. doi: 10.1016/s0161-6420(96)30548-4.
4
New issues in the management of cytomegalovirus retinitis in AIDS patients.
Am J Health Syst Pharm. 1998 Feb 15;55(4):392-5. doi: 10.1093/ajhp/55.4.392.
5
Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS.
Drugs. 1999 Aug;58(2):325-45. doi: 10.2165/00003495-199958020-00015.
6
Cidofovir in the treatment of cytomegalovirus (CMV) retinitis.
Ocul Immunol Inflamm. 1998 Sep;6(3):195-203. doi: 10.1076/ocii.6.3.195.4036.
7
New therapies for cytomegalovirus retinitis.
Int Ophthalmol Clin. 1996 Spring;36(2):1-9. doi: 10.1097/00004397-199603620-00003.
8
The changing treatment options for CMV retinitis.
GMHC Treat Issues. 1995 Jul-Aug;9(7/8):1-8.
9
Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
N Engl J Med. 1997 Jul 10;337(2):105-14. doi: 10.1056/NEJM199707103370207.
10
Promising new treatments for cytomegalovirus retinitis.
JAMA. 1995 May 10;273(18):1457-9.
引用本文的文献
1
Cytomegalovirus retinitis in the highly active anti-retroviral therapy era.
Ann Eye Sci. 2022 Mar;7. doi: 10.21037/aes-21-18.
2
A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency.
J Virol. 1999 Jul;73(7):5663-70. doi: 10.1128/JVI.73.7.5663-5670.1999.
本文引用的文献
1
Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial.
Ann Intern Med. 1997 Feb 15;126(4):257-63. doi: 10.7326/0003-4819-126-4-199702150-00001.
2
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group.
N Engl J Med. 1996 Jun 6;334(23):1491-7. doi: 10.1056/NEJM199606063342302.
3
A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS.
J Infect Dis. 1993 Aug;168(2):444-8. doi: 10.1093/infdis/168.2.444.
4
Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial.
Arch Ophthalmol. 1994 Dec;112(12):1531-9. doi: 10.1001/archopht.1994.01090240037023.
5
Detection of cytomegalovirus DNA in serum correlates with clinical cytomegalovirus retinitis in AIDS.
J Infect Dis. 1994 Nov;170(5):1271-4. doi: 10.1093/infdis/170.5.1271.
6
Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis.
J Infect Dis. 1995 Jan;171(1):177-82. doi: 10.1093/infdis/171.1.177.
7
Foscarnet decreases human immunodeficiency virus RNA.
J Infect Dis. 1995 Jul;172(1):225-7. doi: 10.1093/infdis/172.1.225.
8
Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group.
N Engl J Med. 1995 Sep 7;333(10):615-20. doi: 10.1056/NEJM199509073331002.
9
Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents.
Antimicrob Agents Chemother. 1988 Jul;32(7):1025-30. doi: 10.1128/AAC.32.7.1025.
10
Foscarnet nephrotoxicity: mechanism, incidence and prevention.
Am J Nephrol. 1989;9(4):316-21. doi: 10.1159/000167987.
Zotero 插件